Recent Updates
Recently added Catalysts
INDV Positive Sentiment Score: 70/100

Indivior Announces Q1 2023 Financial Results Indivior PLC (LSE: INDV) today announced its financial results for the period ending March 31, 2023. The earnings release, investor presentation and...

Key Takeaway: Indivior PLC announced its financial results for Q1 2023, highlighting ongoing initiatives in its business. The company is focused on treating substance use disorders and serious mental illnesses. Additionally, Indivior is working on expanding its pipeline of product candidates to address various chronic conditions. The earnings release and additional resources are available for investors and interested parties.

Market Sentiment Analysis

POSITIVE FACTORS

  • Indivior reported its financial results for Q1 2023, showcasing ongoing business activities.
  • The company continues to develop treatments for substance use disorders and mental illnesses.
  • Indivior is expanding its portfolio and pipeline, indicating a proactive growth strategy.

Full Press Release Details

SLOUGH, U.K. , and Richmond, Va. , April 27, 2023 /PRNewswire/ -- Indivior PLC (LSE: INDV) today announced its financial results for the period ending March 31, 2023 . The earnings release, investor presentation and webcast are available at www.indivior.com .
There will be a live webcast presentation at 13:00 BST ( 8:00 am EST ) hosted by Mark Crossley , CEO. The details are below.
Participants may access the presentation telephonically by registering with the following link: https://register.vevent.com/register/BIa24873f5a1524c73b34c473b7761725f
(Please note this is a change from prior calls - registrants will have an option to be called back directly immediately prior to the call or be provided a call-in # with a unique pin code following their registration)
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid use disorder treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and cooccurring disorders of SUD. Headquartered in the United States in Richmond, VA , Indivior employs more than 1,000 individuals globally and its portfolio of products is available in 39 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior .
SOURCE Indivior PLC

21 %

Frequently Asked Questions

What were Indivior's financial results announcement date?

Indivior announced its financial results on April 27, 2023.

Where can I access Indivior's earnings release and webcast?

You can access the earnings release and webcast at www.indivior.com.

What is Indivior's focus as a pharmaceutical company?

Indivior focuses on developing medicines for substance use disorders and serious mental illnesses.

How many countries is Indivior's product portfolio available in?

Indivior's products are available in 39 countries worldwide.

Who is hosting the live webcast presentation?

The live webcast presentation is hosted by Mark Crossley, CEO of Indivior.

Last updated: Apr 27, 2023